Clinical Trial Update: COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial (COMBAT-NORSE) comparing anakinra and tocilizumab for New Onset Refractory Status Epilepticus, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Febrile Infection-related Epilepsy Syndrome
• New Onset Refractory Status Epilepticus

Drugs mentioned

• Actemra (tocilizumab)
• KINERET (ANAKINRA)

Snippet

Sponsor: Yale University | Conditions: New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus | Phase 3 | Status: NOT_YET_RECRUITING